U.S. Markets open in 5 hrs 5 mins

Wired News – Exelixis’ Partner Ipsen Gets EMA Validation of the Application for a New Indication for CABOMETYX

Stock Monitor: ChemoCentryx Post Earnings Reporting

LONDON, UK / ACCESSWIRE / April 02, 2018 / Active-Investors.com has just released a free research report on Exelixis, Inc. (NASDAQ: EXEL). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=EXEL as the Company's latest news hit the wire. On March 28, 2018, the Company, which is a commercially-successful, oncology-focused, biotechnology organization, announced that its partner, Ipsen, has received the European Medicines Agency (EMA)'s validation of the application for a new indication for CABOMETYX® (cabozantinib) for previously treated advanced hepatocellular carcinoma (HCC). Register today and get access to over 1000 Free Research Reports by joining our site below:


Active-Investors.com is currently working on the research report for ChemoCentryx, Inc. (NASDAQ: CCXI), which also belongs to the Healthcare sector as the Company Exelixis. Do not miss out and become a member today for free to access this upcoming report at:


Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Exelixis most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:


About Hepatocellular Carcinoma (HCC)

HCC is the most common type of primary liver cancer in adults, and it is the most common cause of death in people with cirrhosis. Liver cancer accounts for over 700,000 deaths every year and the incidence of liver cancer has more than tripled in the US since 1980.

However, this patient community has very little treatment options. Patients suffering with HCC normally survive for less than 6 months without treatment.

About CABOMETYX® (Cabozantinib)

CABOMETYX® is an oral small molecule inhibitor of receptors, including VEGFR, MET, AXL, and RET. Cabozantinib constrains the activity of these receptors, which are involved in normal cellular function and pathologic processes, such as tumor angiogenesis, invasiveness, metastasis, and drug resistance.

About the CELESTIAL Study

The CELESTIAL trial was a randomized, double blind, placebo-controlled study for evaluating the safety and efficacy of Cabozantinib in patients with advanced HCC. The CELESTIAL trial was conducted at over 100 sites in 19 countries. The trial enrolled a total of 760 patients with advanced HCC who received prior sorafenib, may have received up to two prior systemic cancer therapies for HCC, and had adequate liver function. Exelixis completed the enrollment for this study in September 2017.

In the CELESTIAL trial, patients were randomized 2:1 to receive 60 mg of Cabozantinib once daily or placebo. Patients were stratified on the basis of etiology of the disease (hepatitis C, hepatitis B, or other), geographic region (Asia versus other regions), and presence of extrahepatic spread and/or macrovascular invasion (yes or no).

However, cross over was not allowed between the study arms during the blinded treatment phase of the trial. The primary endpoint was overall survival (OS), while the secondary endpoints included objective response rate and progression-free survival. Exploratory endpoints included patient-reported outcomes, biomarkers, and safety.

Filing Based on Positive Results from CELESTIAL Trial

The filing for the new indication of Cabozantinib is based on positive top-line data from the global pivotal Phase-3 CELESTIAL trial. This trial met its primary endpoint of overall survival, with Cabozantinib providing a statistically significant and clinically meaningful improvement in OS versus placebo in patients with advanced HCC, and who had been previously treated with sorafenib (pre-specified critical p-value ≤ 0.021).

Milestone Payment for Exelixis

The marketing authorization from the EMA marks a significant milestone in Exelixis' collaboration and development program with Ipsen. This will allow the Companies to extend the usage of Cabozantinib to additional patient populations outside of the currently approved indication.

As per the terms of the Collaboration and License Agreement with Ipsen, Exelixis is entitled to receive a milestone payment of $10 million subsequent to the acceptance of this filing. As per the new revenue recognition standards adopted by Exelixis in the first quarter of 2018, the Company will not record this amount as revenue but expects Ipsen to make the payment in the second quarter of this year.

FDA Granted Orphan Drug Designation to Cabozantinib

On March 06, 2017, the US Food and Drug Administration (FDA) granted an orphan drug designation to Cabozantinib for the treatment of advanced HCC. However, Exelixis declared on October 16, 2017, that the independent data monitoring committee for the CELESTIAL study has suggested that the trial should be stopped for efficacy after the review at the second planned interim analysis.

Submission of sNDA for Cabozantinib

On March 15, 2018, Exelixis declared that it had completed the submission of a supplemental New Drug Application (sNDA) to the FDA for Cabozantinib for previously treated advanced HCC. The submission was based on the findings from the CELESTIAL trial. If the sNDA gets approved, it will allow the drug sponsor to make changes to the previously approved product label, including modifications to the indication.

Stock Performance Snapshot

March 29, 2018 - At Thursday's closing bell, Exelixis' stock slightly dropped 0.94%, ending the trading session at $22.15.

Volume traded for the day: 4.84 million shares, which was above the 3-month average volume of 2.89 million shares.

Stock performance in the past twelve-month period – up 4.83%

After last Thursday's close, Exelixis' market cap was at $6.62 billion.

Price to Earnings (P/E) ratio was at 44.84.

The stock is part of the Healthcare sector, categorized under the Biotechnology industry. This sector was up 0.5% at the end of the session.


Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.


A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visithttp://active-investors.com/legal-disclaimer/.


For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors